Grant: Doctoral Award: Doctoral Foreign Study Award (DFSA)
Direct Payment
$105,000.00
Leveraging single nuclei expression signatures and assays of disease progression to explore mechanisms of prophylactic and therapeutic intervention targeting the inflammatory response in a mouse model of Parkinson Disease
FY 2021-22
Summary
Parkinson disease (PD) follows Alzheimer disease as the second most common neurodegenerative disease in Canada and affects over 10 million people worldwide. PD is characterized by a loss of neurons in a region of the brain called the substantia nigra. Patients diagnosed with PD exhibit debilitating movement-related symptoms - including shaking, muscle stiffness, and difficulties with walking and coordination - that begin during middle age and worsen over time. As such, there is a critical need to develop strategies that will prevent/slow PD onset and disease progression in the aging population. A major roadblock preventing the development of broadly applicable therapeutics for PD is the fact that PD is caused by a wide range of genetic and environmental factors that result in individual differences in disease risk, age of onset, and progression. Notably, inflammation has been increasingly acknowledged as a common driver of neurodegeneration caused by a range of genetic and environmental risk factors. Therefore, targeting this inflammatory response may represent a promising avenue of prophylactic and therapeutic intervention that has the potential to improve the duration and quality of life in the aging Canadian population at risk for PD and other neurodegenerative disorders. This project will investigate the potential of an anti-inflammatory drug (Ibuprofen) to prevent the onset and slow the progression of PD. This is the first study of its kind to characterize the effect of an anti-inflammatory drug by defining how it modulates gene expression, as well as clinical onset and progression of PD in a mouse model. This novel study will identify genes, pathways, and disease outcomes associated with targeting the inflammatory response in PD. The results of this research will lay groundwork to inform the development and implementation of strategies that may extend the quality of life of individuals at risk for PD and other neurodegenerative disorders.
Department
Program
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Recipient
Location
Maryland, United States of America
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
457118
Name
Boyd Rachel J
Region
Maryland
Country
United States of America
Orgtype
Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Leveraging single nuclei expression signatures and assays of disease progression to explore mechanisms of prophylactic and therapeutic intervention targeting the inflammatory response in a mouse model of Parkinson Disease
Programtype2
Studentship Programs
Orgnameinp2
Direct Payment
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Award: Doctoral Foreign Study Award (DFSA)
Keyworddelim
Bioinformatics; Disease Onset; Histology; Inflammatory Response; Neurodegeneration; Non-Steroidal Anti-Inflammatory Drugs; Parkinson Disease; Prophylatic Intervention; Single-Nucleus Rna Sequencing; Transcriptomics
Abstract
Parkinson disease (PD) follows Alzheimer disease as the second most common neurodegenerative disease in Canada and affects over 10 million people worldwide. PD is characterized by a loss of neurons in a region of the brain called the substantia nigra. Patients diagnosed with PD exhibit debilitating movement-related symptoms - including shaking, muscle stiffness, and difficulties with walking and coordination - that begin during middle age and worsen over time. As such, there is a critical need to develop strategies that will prevent/slow PD onset and disease progression in the aging population. A major roadblock preventing the development of broadly applicable therapeutics for PD is the fact that PD is caused by a wide range of genetic and environmental factors that result in individual differences in disease risk, age of onset, and progression. Notably, inflammation has been increasingly acknowledged as a common driver of neurodegeneration caused by a range of genetic and environmental risk factors. Therefore, targeting this inflammatory response may represent a promising avenue of prophylactic and therapeutic intervention that has the potential to improve the duration and quality of life in the aging Canadian population at risk for PD and other neurodegenerative disorders. This project will investigate the potential of an anti-inflammatory drug (Ibuprofen) to prevent the onset and slow the progression of PD. This is the first study of its kind to characterize the effect of an anti-inflammatory drug by defining how it modulates gene expression, as well as clinical onset and progression of PD in a mouse model. This novel study will identify genes, pathways, and disease outcomes associated with targeting the inflammatory response in PD. The results of this research will lay groundwork to inform the development and implementation of strategies that may extend the quality of life of individuals at risk for PD and other neurodegenerative disorders.
Competitiondate
202110
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Boyd, Rachel J
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~